Bromocryptine in levodopa response-losing parkinsonism. A double blind study

Area of Science:

• Neurology
• Pharmacology

Background:

• Parkinson's disease (PD) is a progressive neurodegenerative disorder.
• Levodopa is a primary treatment, but efficacy can decline over time.
• Some patients exhibit insufficient or deteriorating responses to optimal levodopa therapy.

Purpose of the Study:

• To evaluate the efficacy of bromocryptine as an add-on therapy in advanced Parkinson's disease patients with inadequate levodopa response.
• To assess the impact of high-dose bromocryptine on motor and global assessments in this patient population.

Main Methods:

• A 5-month, double-blind study involving 23 patients with advanced Parkinson's disease.
• Patients had optimal, stabilized levodopa dosages prior to and during the study.
• Bromocryptine was added at high doses (average 71 mg/day).

Main Results:

• Significant improvements were observed in the total scores of the Webster rating scale and the Neurological Unified Dyskinesia Scale (NUDS).
• Both investigator and patient global assessments indicated significant improvement in disease status.
• No prior double-blind trials had established bromocryptine's efficacy in this specific patient group.

Conclusions:

• Bromocryptine significantly enhances the therapeutic effectiveness of levodopa in Parkinson's disease patients experiencing suboptimal responses.
• High-dose bromocryptine represents a viable therapeutic option for managing advanced Parkinson's disease with levodopa resistance.